CVS Health® Becomes First Healthcare Company to Earn URAC Health Equity Accreditation
CVS Health is the first healthcare company to receive Health Equity accreditation from URAC, recognizing the work done through CVS Caremark and CVS Specialty. URAC sets high standards in healthcare…
Novartis Tops 2024 Access to Medicine Index
Novartis has secured the top spot in the 2024 Access to Medicine Index (ATMI), highlighting the company’s leadership in enhancing global access to medicines. The Access to Medicine Index, published…
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab with Berahyaluronidase Alfa
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial, which assessed the noninferiority of subcutaneous pembrolizumab,…
Bayer Expands Cardiovascular Portfolio with Cytokinetics Aficamten in Japan
Bayer and Cytokinetics, Inc. (Nasdaq: CYTK) have announced a collaboration and license agreement for the exclusive development and commercialization of aficamten in Japan. Aficamten is a cardiac myosin inhibitor being…
BeiGene Announces Settlement with Generic Filer of BRUKINSA
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne Medicines Ltd., has announced a settlement agreement with MSN Pharmaceuticals,…
Astellas Shares Update on IZERVAY™ Supplemental New Drug Application
Astellas Pharma Inc. (TSE: 4503) announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on November 15, 2024, regarding the supplemental New Drug Application…
Dapirolizumab Pegol Phase 3 Data Highlights SLE Disease Activity Reduction
UCB and Biogen have unveiled detailed Phase 3 results for dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate, demonstrating significant improvements in managing moderate-to-severe systemic lupus erythematosus (SLE). Findings…
WHO Investment Round: A Defining Moment at G20 Summit with Leaders’ Pledges
The World Health Organization’s (WHO) first-ever Investment Round reached a pivotal milestone at the G20 Leaders’ Summit in Rio de Janeiro. Chaired by Brazilian President H.E. Luiz Inácio Lula da…
CVS Health Announces New Board Appointments
CVS Health® (NYSE: CVS) announced the addition of four new members to its Board of Directors: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman. These appointments follow collaborative discussions…
Lilly’s Muvalaplin Reduces Lipoprotein(a) by Up to 85% in High-Risk Adults
Eli Lilly and Company (NYSE: LLY) has revealed encouraging Phase 2 results for muvalaplin, an investigational once-daily oral inhibitor targeting lipoprotein(a) [Lp(a)], a hereditary risk factor for cardiovascular disease. The…
Celltrion Shares Phase III Data on Denosumab and Tocilizumab Biosimilars at ACR 2024
Celltrion presented new findings from Phase III randomized controlled trials (RCTs) for its biosimilar candidates CT-P41 (referencing PROLIA®/XGEVA® for postmenopausal osteoporosis) and CT-P47 (referencing ACTEMRA® for moderate-to-severe rheumatoid arthritis) at…
Astellas Updates on IZERVAY™ (Avacincaptad Pegol) Supplemental NDA
Astellas Pharma Inc. (TSE: 4503) announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the supplemental New Drug Application (sNDA) for IZERVAY™…